Genzyme to Market Elaprase in Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Genzyme Corp. has gotten approval from the Japanese government to begin distributing Elaprase in Japan. As part of a deal with Shire Human Genetic Therapies, Genzyme will market Elaprase in Asia. In addition to Japan, Genzyme expects to receive approval for the drug in Australia by the end of 2007, as well as Taiwan and South Korea in 2008. Elaprase is used to treat patients with Hunter syndrome, a rare genetic disorder that causes severe and eventually fatal damage to tissues and organs. Genzyme has been doing business in Japan for 20 years and currently has about 100 employees working in the country. Elaprase is the fifth enzyme replacement therapy the company has introduced there. (Click here for more
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.